Cargando…

Allium sativum Compared to Cilostazol as an Inhibitor of Myointimal Hyperplasia

OBJECTIVE: Intimal hyperplasia is associated with graft failure and vascular sutures in the first year after surgery and in postangioplasty restenosis. Allium sativum (common garlic) lowers cholesterol and has antioxidant effects; it also has antiplatelet and antitumor properties and, therefore, has...

Descripción completa

Detalles Bibliográficos
Autores principales: Lima, Paulo Roberto da Silva, Bandeira, Francisco Chavier Vieira, Rolim, Janio Cipriano, Nogueira, Manuel Ricardo Sena, Pordeus, Mizael Armando Abrantes, de Oliveira, Andressa Feitosa Bezerra, Pitta, Guilherme Benjamin Brandão
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Cirurgia Cardiovascular 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094421/
https://www.ncbi.nlm.nih.gov/pubmed/27849301
http://dx.doi.org/10.5935/1678-9741.20160069
_version_ 1782465101239943168
author Lima, Paulo Roberto da Silva
Bandeira, Francisco Chavier Vieira
Rolim, Janio Cipriano
Nogueira, Manuel Ricardo Sena
Pordeus, Mizael Armando Abrantes
de Oliveira, Andressa Feitosa Bezerra
Pitta, Guilherme Benjamin Brandão
author_facet Lima, Paulo Roberto da Silva
Bandeira, Francisco Chavier Vieira
Rolim, Janio Cipriano
Nogueira, Manuel Ricardo Sena
Pordeus, Mizael Armando Abrantes
de Oliveira, Andressa Feitosa Bezerra
Pitta, Guilherme Benjamin Brandão
author_sort Lima, Paulo Roberto da Silva
collection PubMed
description OBJECTIVE: Intimal hyperplasia is associated with graft failure and vascular sutures in the first year after surgery and in postangioplasty restenosis. Allium sativum (common garlic) lowers cholesterol and has antioxidant effects; it also has antiplatelet and antitumor properties and, therefore, has great potential to reduce or inhibit intimal hyperplasia of the arteries. Our objective is to determine if the garlic has an efficacy to inhibit myointimal hyperplasia compared to cilostazol. METHODS: Female New Zealand rabbits were divided into the following groups (n=10 each) according to treatment: group A, garlic, 800 µg×kg-(1)×day-(1), orally; group C, cilostazol, 50 mg.day-(1), orally; group PS, 10 ml of 0.9% physiological saline solution, orally. Our primary is the difference of the mean of myointimal hyperplasia. Statistical analysis was performed by using ANOVA and Tukey tests, as well as the Chi-square test. We calculated the 95% confidence interval for each point estimate, and the P value was set as < 0.05. RESULTS: Group PS had a mean hyperplasia rate of 35.74% (95% CI, 31.76–39.71%); group C, 16.21% (95% CI, 13.36–19.05%); and group A, 21.12% (95% CI, 17.26–25.01%); P<0.0001. CONCLUSION: We conclude that Allium sativum had the same efficacy in inhibiting myointimal hyperplasia when compared to the positive control, cilostazol.
format Online
Article
Text
id pubmed-5094421
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Sociedade Brasileira de Cirurgia Cardiovascular
record_format MEDLINE/PubMed
spelling pubmed-50944212016-11-04 Allium sativum Compared to Cilostazol as an Inhibitor of Myointimal Hyperplasia Lima, Paulo Roberto da Silva Bandeira, Francisco Chavier Vieira Rolim, Janio Cipriano Nogueira, Manuel Ricardo Sena Pordeus, Mizael Armando Abrantes de Oliveira, Andressa Feitosa Bezerra Pitta, Guilherme Benjamin Brandão Braz J Cardiovasc Surg Original Article OBJECTIVE: Intimal hyperplasia is associated with graft failure and vascular sutures in the first year after surgery and in postangioplasty restenosis. Allium sativum (common garlic) lowers cholesterol and has antioxidant effects; it also has antiplatelet and antitumor properties and, therefore, has great potential to reduce or inhibit intimal hyperplasia of the arteries. Our objective is to determine if the garlic has an efficacy to inhibit myointimal hyperplasia compared to cilostazol. METHODS: Female New Zealand rabbits were divided into the following groups (n=10 each) according to treatment: group A, garlic, 800 µg×kg-(1)×day-(1), orally; group C, cilostazol, 50 mg.day-(1), orally; group PS, 10 ml of 0.9% physiological saline solution, orally. Our primary is the difference of the mean of myointimal hyperplasia. Statistical analysis was performed by using ANOVA and Tukey tests, as well as the Chi-square test. We calculated the 95% confidence interval for each point estimate, and the P value was set as < 0.05. RESULTS: Group PS had a mean hyperplasia rate of 35.74% (95% CI, 31.76–39.71%); group C, 16.21% (95% CI, 13.36–19.05%); and group A, 21.12% (95% CI, 17.26–25.01%); P<0.0001. CONCLUSION: We conclude that Allium sativum had the same efficacy in inhibiting myointimal hyperplasia when compared to the positive control, cilostazol. Sociedade Brasileira de Cirurgia Cardiovascular 2016 /pmc/articles/PMC5094421/ /pubmed/27849301 http://dx.doi.org/10.5935/1678-9741.20160069 Text en http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Lima, Paulo Roberto da Silva
Bandeira, Francisco Chavier Vieira
Rolim, Janio Cipriano
Nogueira, Manuel Ricardo Sena
Pordeus, Mizael Armando Abrantes
de Oliveira, Andressa Feitosa Bezerra
Pitta, Guilherme Benjamin Brandão
Allium sativum Compared to Cilostazol as an Inhibitor of Myointimal Hyperplasia
title Allium sativum Compared to Cilostazol as an Inhibitor of Myointimal Hyperplasia
title_full Allium sativum Compared to Cilostazol as an Inhibitor of Myointimal Hyperplasia
title_fullStr Allium sativum Compared to Cilostazol as an Inhibitor of Myointimal Hyperplasia
title_full_unstemmed Allium sativum Compared to Cilostazol as an Inhibitor of Myointimal Hyperplasia
title_short Allium sativum Compared to Cilostazol as an Inhibitor of Myointimal Hyperplasia
title_sort allium sativum compared to cilostazol as an inhibitor of myointimal hyperplasia
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094421/
https://www.ncbi.nlm.nih.gov/pubmed/27849301
http://dx.doi.org/10.5935/1678-9741.20160069
work_keys_str_mv AT limapaulorobertodasilva alliumsativumcomparedtocilostazolasaninhibitorofmyointimalhyperplasia
AT bandeirafranciscochaviervieira alliumsativumcomparedtocilostazolasaninhibitorofmyointimalhyperplasia
AT rolimjaniocipriano alliumsativumcomparedtocilostazolasaninhibitorofmyointimalhyperplasia
AT nogueiramanuelricardosena alliumsativumcomparedtocilostazolasaninhibitorofmyointimalhyperplasia
AT pordeusmizaelarmandoabrantes alliumsativumcomparedtocilostazolasaninhibitorofmyointimalhyperplasia
AT deoliveiraandressafeitosabezerra alliumsativumcomparedtocilostazolasaninhibitorofmyointimalhyperplasia
AT pittaguilhermebenjaminbrandao alliumsativumcomparedtocilostazolasaninhibitorofmyointimalhyperplasia